These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 3416080

  • 21. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
    Leonard JP, Neben TY, Kozitza MK, Quinto CM, Goldman SJ.
    Exp Hematol; 1996 Feb; 24(2):270-6. PubMed ID: 8641352
    [Abstract] [Full Text] [Related]

  • 22. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model.
    Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL.
    Thromb Haemost; 1997 May; 77(5):1020-4. PubMed ID: 9184421
    [Abstract] [Full Text] [Related]

  • 23. Higher erythropoietin secretion in response to cobaltous chloride in post-hypoxic than in hypertransfused polycythemic mice.
    Alippi RM, Boyer P, Leal T, Barcelò AC, Martinez MP, Bozzini CE.
    Haematologica; 1992 May; 77(6):446-9. PubMed ID: 1289180
    [Abstract] [Full Text] [Related]

  • 24. Reticulocyte changes after experimental anemia and erythropoietin treatment of horses.
    Cooper C, Sears W, Bienzle D.
    J Appl Physiol (1985); 2005 Sep; 99(3):915-21. PubMed ID: 16103516
    [Abstract] [Full Text] [Related]

  • 25. Biological effects of recombinant erythropoietin, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 on purified rat megakaryocytes.
    Ishida Y, Yano S, Yoshida T, Tanaka H, Yamada Y, Kawano M, Kaneko T, Matsumoto N.
    Exp Hematol; 1991 Aug; 19(7):608-12. PubMed ID: 1893946
    [Abstract] [Full Text] [Related]

  • 26. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
    Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA.
    Exp Hematol; 2003 Apr; 31(4):290-9. PubMed ID: 12691916
    [Abstract] [Full Text] [Related]

  • 27. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.
    Blood; 1996 Jul 15; 88(2):511-21. PubMed ID: 8695799
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
    Ait-Oudhia S, Scherrmann JM, Krzyzanski W.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):897-910. PubMed ID: 20501635
    [Abstract] [Full Text] [Related]

  • 32. Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment.
    Nijhof W, Goris H, Dontje B, Dresz J, Loeffler M.
    Exp Hematol; 1993 Apr 01; 21(4):496-501. PubMed ID: 8462658
    [Abstract] [Full Text] [Related]

  • 33. Erythropoietin and platelet production.
    Beguin Y.
    Haematologica; 1999 Jun 01; 84(6):541-7. PubMed ID: 10366799
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.
    McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL.
    Blood; 1990 Nov 01; 76(9):1718-22. PubMed ID: 2224121
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.